Form 8-K Amylyx Pharmaceuticals, For: Mar 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
March 8, 2024 2:35 PM ESTGoldman Sachs analyst Corinne Jenkins downgraded Amylyx Pharmaceuticals inc. (NASDAQ: AMLX) from Buy to Neutral with a price target of $4.00 (from $40.00).
The analyst comments "This morning, AMLX reported that the Ph3 PHOENIX trial evaluating the use of Relyvrio in patients with amyotrophic lateral sclerosis (ALS) did not meet its primary or secondary endpoints... More
